Navigation Links
Neurobiological Technologies Announces FDA Agreement to Consolidate Viprinex Phase 3 Trials Accelerating Time to Pivotal Data
Date:10/13/2008

robiological Technologies, Inc.

Neurobiological Technologies, Inc., (Nasdaq: NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases, rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, including the inability to enroll patients at anticipated rates, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neurobiological Technologies Reaches Patient Enrollment Target For Interim Analysis of Viprinex(TM) Phase 3 Stroke Trials
2. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
3. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
4. Neurobiological Technologies, Inc. and Buck Institute Partner to Develop Novel Treatment for Alzheimers Disease
5. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
6. ImmunoVaccine Technologies DepoVax(TM) Shows Positive Results for Cancer and Infectious Diseases
7. Wound Management Technologies, Inc. Announces Conference Plans in Boston and Additional Clinical Research on CellerateRx(R)
8. Experts Assert That Varian Technologies Deliver Speed and Clinical Accuracy in Treating Cancer Patients
9. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
10. BioSpecifics Technologies Corp. Announces Initiation of Phase IIb Trial for Peyronies Disease
11. New CyberKnife Technologies Demonstrate Dramatic Reduction in Treatment Times
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  In an unprecedented effort to curb the spread of "superbugs" such ... vehicles, an advanced and portable UV germicidal lamp manufactured by MRSA-UV ... In order to prevent EMS paramedics and transport ... West Palm Beach Fire Rescue is the first in ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Analysis http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... , NEW YORK, Nov. 17 ... research report is available in its catalogue. ... Biomaterials 2009 (15 Countries) , ... 2008, the combined European biomaterial market was ...
... , BEIJING, ... developer and provider of vaccines in China, announced today that ... Administration,for Panflu.1, the Company,s H1N1 vaccine. The population has been ... for PANFLU.1 was extended to,one year from six months. , ...
Cached Medicine Technology:Reportlinker Adds European Markets for Orthopedic Biomaterials 2009 (15 Countries) 2Sinovac's PANFLU.1 (H1N1) Regulatory Approval Expanded to Include Geriatric Population 2
(Date:7/9/2014)... almost all types of cancer sends the protein factories ... a tumour,s uncontrolled growth, new research suggests. , Scientists ... molecular trigger responsible for ratcheting up activity of the ... the building blocks cancer cells need to keep growing. ... SREBP, controls the flow of messages to the endoplasmic ...
(Date:7/9/2014)... type of lung cancer, researchers have uncovered mutations in ... tumors. The new knowledge may expand treatments for patients ... are available or are in clinical trials. , Reporting ... Cancer Genome Atlas (TCGA), including researchers at Washington University ... and other institutions, studied tumors from 230 patients with ...
(Date:7/9/2014)... a relatively optimistic picture of women,s chances of surviving ... the chest wall or skin, but not beyond. ... size and whether they have involved lymph nodes, are ... advanced" tumors, suggesting that they are a relatively serious ... breast cancers of this and other types account for ...
(Date:7/9/2014)... BostonPractices used in policing injection drug users in ... mortality. , A study, conducted by researchers ... Health, in collaboration with St. Petersburg Pavlov State ... had on the health outcomes of a cohort ... use. , Those who were arrested by police ...
(Date:7/9/2014)... feelings are personal and subjective, the human brain ... represents emotions across different senses, situations and even ... neuroscientist Adam Anderson. , "We discovered that fine-grained ... an area of the brain associated with emotional ... an individual,s subjective feeling," says Anderson, associate professor ...
Breaking Medicine News(10 mins):Health News:Signal may send cancer's cellular factories into overdrive 2Health News:Lung cancer study hints at new treatments 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 2Health News:Fox Chase researchers recommend updating the staging criteria for breast cancer diagnoses 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Study cracks how the brain processes emotions 2
... (HealthDay News) -- Men with high amounts of the controversial ... have impaired semen quality, a new study of factory workers ... National Institute of Occupational Safety and Health, found high urine ... drop in sperm concentration, overall sperm count, sperm vitality and ...
... Wisconsin are conducting the KAST clinical trial at ... of a new vertebral augmentation treatment (Kiva) for ... Sean Tutton, M.D, associate professor ... is principal interventional radiology investigator for this multi-institutional, ...
... Reporter , THURSDAY, Oct. 28 (HealthDay News) -- Better treatments are ... AIDS-causing virus takes a toll that will challenge the health care ... HIV-positive men and women ages 50 and older living in New ... much higher rate than others their age without HIV. And ...
... in everything from laws about using your cell phone while ... pass on fourth down come to Austin on November 7, ... people who use math for a living but also problem ... of the Institute for Operations Research and the Management Sciences ...
... to different prescription drug plans because Part D reimbursements ... the actual costs incurred, according to a study released ... describes how a system designed to encourage competition and ... led companies to raise their premiums in an effort ...
... HealthDay Reporter , THURSDAY, Oct. 28 (HealthDay News) -- ... might help protect women from breast cancer, a new, ... "We found no overall association between green tea intake ... who have habitually drunk green tea," said lead researcher ...
Cached Medicine News:Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 2Health News:Plastics Chemical BPA Tied to Poor Sperm Quality 3Health News:National research study to assess new treatment for painful vertebral fractures 2Health News:More Older Americans Living With HIV 2Health News:More Older Americans Living With HIV 3Health News:4,000 numbers crunchers count on Austin 2Health News:Study identifies flaws in Medicare prescription drug program 2Health News:Study Finds Green Tea Offers No Protection From Breast Cancer 2
Sabre 180, 230V, 50Hz is a powerful niche generator....
High performance capabilities in a multipurpose generator, blended cut modes, simultaneous independent coagulation, low voltage coagulation, valleylab REM safety substantially reduces the risk of pat...
Lorgnette pinhole occluder...
Black multi-pinhole occluder...
Medicine Products: